Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...
Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...
Adagio Medical has reported positive six-month data from its pivotal FULCRUM-VT trial, supporting its plans to seek premarket ...
The average one-year price target for Adagio Medical Holdings (NasdaqCM:ADGM) has been revised to $3.57 / share. This is a decrease of 12.50% from the prior estimate of $4.08 dated April 12, 2026. The ...
84% Freedom From Shock and 59% Freedom From VT Recurrence in FULCRUM-VT Pivotal IDE Trial Meet Safety and Effectiveness Endpoints and Replicate CryoCure-VT Results First and Only Ablation Technology ...
Adagio Therapeutics burst onto the scene in 2020 led by biotech veteran Tillman Gerngross, Ph.D., and in direct response to the COVID pandemic. But in the intervening years, much has changed at the ...
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results